cross-hla targeting of intracellular oncoproteins with peptide-centric cars intracellular peptides - assortiment-de-peptide-a-facon-de-criblage-et-de-caracterisation Peptide Centric CAR Advancing Cancer Immunotherapy: Cross-HLA Targeting of Intracellular Oncoproteins with Peptide-Centric CARs

asterwood-peptide-serum The landscape of cancer immunotherapy is continuously evolving, with a particular focus on harnessing the power of the immune system to combat malignant cells2021年11月5日—相关研究结果于2021年11月3日在线发表在Nature期刊上，论文标题为“Cross-HLA targeting of intracellular oncoproteins with peptide-centric CARs”。论文 .... A significant challenge in this endeavor lies in targeting intracellular oncoproteins, which constitute the majority of oncogenic drivers. Traditional immunotherapeutic approaches often struggle to access these targets because they reside within the cell. However, recent advancements in Chimeric Antigen Receptor (CAR) technology, specifically the development of peptide-centric CARs (PC-CARs), are offering a promising new avenue for targeting intracellular oncoproteins.Nature：通过以肽为中心的CAR实现细胞内肿瘤蛋白 ...

This innovative approach, exemplified by the work of M.Retraction Note: Cross-HLA targeting of intracellular ... Yarmarkovich and colleagues, focuses on recognizing peptides derived from intracellular proteins that are presented on the cell surface via Human Leukocyte Antigen (HLA) molecules. This strategy allows for the targeting of these previously inaccessible intracellular targets. The core concept behind peptide-centric CARs is their ability to bind to peptide-HLA (pHLA) complexes. This is a crucial distinction from conventional CARs, which typically target surface proteins directlyStructural principles of peptide-centric chimeric antigen ....

The development of peptide-centric CARs was facilitated by a counter-panning strategy utilizing predicted potentially cross-reactive peptides. This method allowed researchers to identify peptides that could be recognized by CARs across different HLA allotypes.2021年11月8日—Cross-HLA targeting of intracellular oncoproteins with peptide-centric CARs. Nature. 2021 599(7885):477-484. Project Files. FTP GLOBUS. Name. This cross-HLA targeting capability is a significant breakthrough, as it broadens the potential patient population that can benefit from such therapies. By designing CARs that can recognize the same oncoprotein peptide presented by various HLA class I molecules, the therapeutic reach is substantially expanded.New Class of "Peptide-Centric" CAR-T Cells Eradicates ...

A notable success of this approach was demonstrated in the context of neuroblastoma2021年11月3日—These data suggest thatpeptide-centric CARshave the potential to vastly expand the pool of immunotherapeutic targets to include non- .... PC-CARs targeting the neuroblastoma oncoprotein PHOX2B presented on HLA were shown to completely and selectively eliminate neuroblastoma tumors in preclinical models. This specific application highlights the potential of Peptide-centric CARs to target unmutated intracellular proteins, thereby expanding the pool of immunotherapeutic targets. The research indicated that intracellular peptides derived from essential oncoproteins are present in the immunopeptidome of neuroblastomaNew Class of "Peptide-Centric" CAR-T Cells Eradicates .... These antigens, previously considered inaccessible, can now be targeted.

The implications of cross-HLA targeting of intracellular oncoproteins with peptide-centric CARs are vastCross-HLA targeting of intracellular oncoproteins with .... It offers a potential solution for targeting a wider range of cancers driven by intracellular alterations. The ability to overcome the traditional limitations imposed by HLA diversity is a critical step forwardRetraction Note:Cross-HLA targeting of intracellular oncoproteins with peptide-centric CARs. Nature. 2023-11;. Mark Yarmarkovich, Quinlen F Marshall, John M .... This technology aims to break through the conventional HLA constraints, potentially benefiting a larger patient group.

While the initial research published in *Nature* in 2021 showed significant promise, it's important to note that a retraction note was issued in 2023 concerning the article "RETRACTED ARTICLE: Cross-HLA targeting of intracellular oncoproteins with peptide-centric CARs.Intracellular Oncoproteins - Peptide-Centric CARs" Despite this retraction, the fundamental concept of targeting intracellular oncoproteins via peptide-HLA complexes with engineered T cells continues to be an active area of research.(PDF) Retraction Note: Cross-HLA targeting of intracellular ... The underlying principle of peptide-centric CARs and their ability to engage peptides presented by different HLAs remains a valuable area of investigation in the pursuit of more effective cancer treatments. Further research into the structural principles of these CARs is ongoing, aiming to engineer CARs with optimal recognition of tumor-associated antigens in the context of diverse HLAs. This ongoing exploration seeks to refine the design of CARs for enhanced efficacy and broader applicability in cancer treatment2021年11月8日—Cross-HLA targeting of intracellular oncoproteins with peptide-centric CARs. Nature. 2021 599(7885):477-484. Project Files. FTP GLOBUS. Name..